A ntithrombin (AT) is a serine protease inhibitor (serpin) and the principal inhibitor of the final common pathway of the coagulation system by inactivation of circulating thrombin (factor IIa) and factor Xa, among other serine proteases. Heparin increases AT activity 2000-to 4000-fold due to a conformational change in the quaternary structure of AT by heparin binding and through formation of a ternary complex of thrombin, AT, and heparin. Heparin-augmented AT activity is still the principal mechanism of anticoagulation for cardiopulmonary bypass (CPB).
AT levels are decreased after administration of heparin due to degradation of the ternary complex. Additionally, acquired AT deficiency is common in patients with critical illness, severe hepatic dysfunction, and after major cardiovascular surgery. 1, 2 The magnitude of reduction in AT after cardiac surgery is similar to that in patients with heterozygous AT deficiency, which is associated with increased risk of thromboembolic events. 3, 4 After cardiac surgery, lower levels of AT have been independently associated with prolonged intensive care unit (ICU) stay and a higher incidence of neurologic and thromboembolic events. 5 We therefore examined for independent association between perioperative AT activity and the frequency of postoperative major adverse cardiac events (MACEs) in patients undergoing coronary artery bypass graft (CABG) surgery.
METHODS
The study cohort was obtained from a continuing prospective longitudinal parent study of 1447 patients undergoing primary CABG surgery with CPB between August 2001 and May 2006 at 2 United States academic medical centers (CABG Genomics Program; http://clinicaltrials.gov/show/NCT00281164). With IRB approval, written informed consent was obtained from each patient. Patients were excluded from the parent study if they were younger than 20 yr old, underwent repeat or off-pump CABG, had a preoperative hematocrit Ͻ25%, or if they had received leukocyte-rich blood products within 30 days before surgery. All patients enrolled in the parent study were included. Patients without postoperative cardiac troponin I (cTnI) levels (n ϭ 43) were excluded from further analysis. Demographic data, medical and surgical history, medications, and outcomes were recorded by trained research staff using defined protocols in a purpose-built case report form. The examination of the relationship between AT levels and MACE was not prespecified in the original parent study.
Perioperative anticoagulation protocols differed between institutions. At Brigham and Women's Hospital, patients received 300 U per kg body weight of porcine heparin to achieve an activated clotting time (ACT) of Ͼ400 s, until February 2004. From February 2004, patients received a Hepcon HMS Plus (Medtronic, Minneapolis, MN) calculated dose of porcine heparin to achieve an ACT of either 300 or 350 s. At Texas Heart Institute, 300 U per kg body weight of either bovine or porcine heparin was given to achieve an ACT of Ͼ400 s.
Clinical End Points for the Test Cohort
The primary clinical end point was prespecified as the occurrence of a MACE, defined as a composite outcome of any one or more of the following: postoperative mortality (defined as all deaths occurring within 30 days of the operation or occurring during the primary hospitalization), reoperation for coronary graft occlusion, myocardial infarction (MI) (predefined as peak postoperative cTnI concentration Ͼ12 ng/mL, being the upper 8th percentile), cardiac arrest (defined as a postoperative event requiring cardiopulmonary resuscitation) until first hospital discharge, thromboembolic event consisting of stroke (defined as a clinical diagnosis of focal or global neurological deficit), or pulmonary embolism (diagnosed by ventilation perfusion scan of moderate to high probability or by a positive pulmonary angiogram).
Cardiac Biomarker Assay
Blood samples were obtained before surgery, 5 min after administration of post-CPB protamine, and on the mornings of postoperative days (PODs) 1-5. Citrated plasma was stored in vapor-phase liquid nitrogen until analysis for cTnI with a sandwich immunoassay on a Triage® platform using monoclonal and polyclonal antibodies (Biosite, San Diego, CA) at a single core facility. Patient caregivers were not aware of the results of the assays as they were performed after patient discharge.
Antithrombin Assays
AT activity was measured with a colorimetric method using a Modular Analytics biochemistry analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY). The assay limit of quantitation was 21.6%. To report human plasma AT activity results in IU/mL, the National Institute for Biological Standards and Control Second International Reference Standard was used to determine a conversion factor of activity in IU/mL ϭ activity in % ϫ 0.0102. AT content was measured using an immunoephelometric method using a BN-100 ProSpec nephelometer (Dade Behring Diagnostics, Marburg, Germany). The assay limit of quantitation was 0.00672 mg/mL. To report human plasma AT content results in IU/mL, the National Institute for Biological Standards and Control Second International Reference Standard was used to determine a conversion factor of content in IU/mL ϭ content in g/L ϫ 3.64. Both assays measure free AT rather than AT complexed with heparin. Assays were performed by Charles River Laboratory in Montreal, Canada by personnel blinded to outcome status. Subsequent comparison of paired AT activity and content data revealed high correlation (r 2 ϭ 0.878), so only the activity is reported.
Statistical Methods
Statistical analyses were performed using SAS, version 9.1.3, and JMP 7.0 (SAS Institute, Cary, NC). AT activity was normally distributed at all time points, so was not transformed. Data are presented as mean (sd) and median with 10%-90% interquantile range, unless otherwise stated. Continuous variables were compared using analysis of variance or Wilcoxon Mann-Whitney ranked sum test when appropriate. Categorical variables were compared with 2 or Fisher's exact test.
Multivariate logistic regression modeling was performed to identify and account for MACE risk factors that might confound any association between low AT activity and MACE. The multivariate analysis used a forward stepwise technique to identify independent risk factors for MACE, whereby clinically relevant demographic variables and variables with a two-tailed univariate P Յ 0.2 were entered into the model and P Յ 0.2 was necessary to remain in the model. Age, gender, race, body mass index, and institution were forced into the model. Nagelkerke generalized r 2 and likelihood ratio test were used to determine the additional predictive value of AT upon MACE. F tests were used to compare generalized r 2 . Odds ratios and 95% confidence intervals for a 0.1 IU/mL decrease in AT activity were estimated. A two-sided P Ͻ 0.05 was considered significant.
RESULTS
The cohort comprised 1403 patients undergoing CABG surgery whose characteristics are described in Table 1 . MACE occurred in 146 patients (10.4%), consisting of postoperative mortality (n ϭ 12), MI (n ϭ 108), stroke (n ϭ 17), pulmonary embolism (n ϭ 8), cardiac arrest (n ϭ 16), or a subsequent postoperative or catheter-based treatment for graft occlusion (n ϭ 6). Nineteen patients had 2 or 3 events, usually MI, with either subsequent death or stroke. Most adverse events occurred before or on POD 2. Of 12 patients with operative mortality, 2 patients died at POD 0 and 10 patients died on or after POD 5. Of 17 patients with stroke, 6 patients had a stroke on or before POD 2. Of 108 patients with MI, 89 patients had a diagnosis of MI first occurring on POD 1. MACE frequency did not differ between institutions (Table 1) .
AT activity and content were measured at the 7 time points ( Table 2) . AT activity at baseline did not differ between patients with MACE (0.91 Ϯ 0.13 IU/mL; n ϭ 146) and those without MACE (0.92 Ϯ 0.13 IU/mL; n ϭ 1257) (P ϭ 0.18). AT activity was significantly reduced at the post-CPB measurement compared with the preoperative time point (P Ͻ 0.0001) and returned to baseline levels over the ensuing 5-day period in patients with and without MACE. Postoperative AT activity was significantly lower in patients with MACE than those without MACE ( Table 2) .
Decreased preoperative AT activity was independently predicted by older age, male gender, and prior heparin use within the same hospitalization (Table 3 ). Other clinical variables that may possibly be indicative of recent heparin use at prior recent hospitalization, such as recent MI, were also independently predictive. Decreased preoperative AT activity was also independently associated with lower platelet count and increased partial thromboplastin time, independent of recent heparin use, perhaps indicating a dose effect of heparin administration upon decreased AT activity. In the 1205 patients who had complete data for all variables in the model, decreased post-CPB AT activity was independently predicted by lower preoperative AT activity and clinical variables that indicate greater hemodilution, such as lower body weight and height and increased transfusion incidence or a prolonged procedure (Table 4 ). A clinical model predicting MACE was developed ( Table 5 ; adjusted r 2 ϭ 0.156) for 1403 patients who had complete data for all variables in the clinical model. Variables that have been associated with MACE in prior studies, notably recent MI, longer perfusion time, a requirement for intraaortic counterpulsation, and red blood cell transfusion were also associated with MACE in this study. AT activities at baseline, post-CPB, PODs 1-5, and the change from baseline at these time points for each patient were added to the clinical model, one time point at a time. Preoperative, post-CPB, and POD 1 AT activity were not independently predictive of MACE, whereas AT activity on PODs 2 and 3 was independently predictive of MACE. MACE was independently associated with change in AT activity from baseline on PODs 2-5 ( Table 5 ). The receiver operating characteristic of the model was significantly improved by the addition of AT activity on PODs 2-4 to the model (Fig. 1) .
DISCUSSION
This prospective, observational, cohort study confirms earlier findings that preoperative AT activity is reduced in patients with recent exposure to heparin or recent MI. 5, 6 Furthermore, AT activity is reduced after CPB, likely due to consumption by heparin administration 6 and dilution. AT activity remained significantly reduced from baseline levels over the postoperative period, recovering to baseline levels within 5 days, on average.
In this population of patients, MACE was associated with factors that have been previously associated with MI or mortality including recent MI, peripheral vascular disease, longer perfusion time, use of intraaortic counterpulsation, and red blood cell transfusion. [7] [8] [9] [10] The clinical model of MACE generated from this cohort had modest predictive value, similar to prior clinical models. 9 The addition of AT activity on POD 2 and beyond to the model modestly improved model performance. However, the clinical value of AT activity as a predictor of MACE is limited by the majority of adverse events that comprised MACE occurring before POD 2. Specifically, the majority of MACE events were MI, which was typically manifested as the peak cTnI level occurring on POD 1. Rather, it may be that lower postoperative AT activity may be a consequence of more extensive surgery and other factors that are associated with increased incidence of MACE, although such assertion cannot be proven in this observational cohort. We cannot exclude the possibility that lower AT levels may have enhanced postoperative MACE. Increased risk of adverse cardiovascular events has been associated with lower levels of AT in other critically ill populations, such as patients with severe sepsis. [11] [12] [13] These observations have prompted clinical trials of supplemental AT administration. 14 -17 Although several trials have shown survival benefit, a meta-analysis of 20 trials encompassing 3458 patients failed to show a survival benefit of administration of AT to critically ill patients. 18 There are limited data regarding AT activity and adverse outcomes after cardiac surgery. The majority of studies describe use of AT for "heparin resistance" during CPB and lack postoperative clinical outcome data. 19 -25 A single well-conducted observational study of 647 patients evaluated the association between preoperative and immediate postoperative AT levels and outcomes in cardiac surgery patients. Low levels of AT activity upon ICU arrival were associated with prolonged ICU stay, higher rate of reexploration for bleeding, thromboembolism, and adverse neurologic sequelae. 5 Our study examined a longer time period that encompassed the period of MACE occurrence and the recovery of AT levels, thus providing additional insights. Importantly, we replicated the finding that AT level after CPB is associated with clinical factors indicative of longer, more extensive procedures, perhaps with more hemodilution. Although our study contributes to our understanding of the role AT plays in the perioperative period, we are concerned by the absence of a temporal correlation between lower AT activity and MACE in our cohort, likely indicating that AT level is not an important determinant of thrombotic complications such as MI, stroke, and graft occlusion in the cardiac surgical setting. Thus, our observational cohort cannot directly address any putative biological mechanism for the role of AT in MACE generation.
CONCLUSION
In a large cohort of patients undergoing CABG surgery, postoperative AT activity was independently associated with MACE. Because this occurs at time points predominantly after the MACE event, the clinical utility of AT as a biomarker of risk remains unknown.
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